$0.00 (0%)

Create a FREE Account to View Full Report

Analyst ForecastNext 12 months ➝Current Price$108.2452-week High$110.7052-week Low$58.59MEAN$97.00-10.38%HIGH$115.00+6.25%LOW$77.00-28.86%
  • Last Price$108.24
  • Previous Close$108.24
  • Change $0.00
  • Open$108.01
  • Volume0
  • Avg. Volume (100-day)6,072,541
  • Market Capitalization$77.04B
  • Days Range
  • 52-week Range $58.59 - $110.70
  • Dividend Yield
  • Ex. Dividend Date
  • P-E13.5
  • EPS8.11
  • Earnings Date01/30/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta0.232
  • PEG Ratio0.52
  • Volatility0.29
  • Average True Range0.02
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.